180 related articles for article (PubMed ID: 16650231)
21. Imatinib mesylate causes hypopigmentation in the skin.
Leong KW; Lee TC; Goh AS
Cancer; 2004 Jun; 100(11):2486-7; author reply 2487-8. PubMed ID: 15160360
[No Abstract] [Full Text] [Related]
22. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
Rastogi MV; Stork L; Druker B; Blasdel C; Nguyen T; Boston BA
Pediatr Blood Cancer; 2012 Nov; 59(5):840-5. PubMed ID: 22378641
[TBL] [Abstract][Full Text] [Related]
24. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
25. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
26. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
[TBL] [Abstract][Full Text] [Related]
27. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
[TBL] [Abstract][Full Text] [Related]
28. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
[No Abstract] [Full Text] [Related]
29. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
30. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.
Kawakami T; Kawanabe T; Soma Y
Acta Derm Venereol; 2009; 89(3):325-6. PubMed ID: 19479144
[No Abstract] [Full Text] [Related]
32. Imatinib mesylate as a cause of acute liver failure.
Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
[TBL] [Abstract][Full Text] [Related]
33. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
34. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
Zaucha JM; Wyrowinska E; Prejzner W; Calbecka M; Hellmann A
Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
[TBL] [Abstract][Full Text] [Related]
35. Skin fragility and blistering with imatinib mesylate.
Verma SM; Murphy G
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):496-8. PubMed ID: 19925597
[No Abstract] [Full Text] [Related]
36. Desensitization to imatinib in patients with leukemia.
Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754
[TBL] [Abstract][Full Text] [Related]
37. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P
Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?
Legros L; Cassuto JP; Ortonne JP
Br J Dermatol; 2005 Sep; 153(3):691-2. PubMed ID: 16120179
[No Abstract] [Full Text] [Related]
39. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
Aleem A
Hematol Oncol Stem Cell Ther; 2009; 2(2):358-61. PubMed ID: 20118061
[TBL] [Abstract][Full Text] [Related]
40. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]